160 likes | 649 Views
Drug Resistance Monitoring . in Cambodia 1997 - 2003. Sensitivity (S or S/RI) at 4 sentinel sites 1991 – 97. Western areas: Battambang, Pursat, Eastern areas: Ratanakiri, Kratie Chloroquine - 1991-93 (West): S or S/RI = 3-12% -1997 (East): S/RI = 76%-86% Fansidar®
E N D
Drug Resistance Monitoring in Cambodia 1997 - 2003
Sensitivity (S or S/RI) at 4 sentinel sites 1991 – 97 Western areas: Battambang, Pursat, Eastern areas: Ratanakiri, Kratie Chloroquine -1991-93 (West): S or S/RI = 3-12% -1997 (East): S/RI = 76%-86% Fansidar® -1991-95 (West): S or S/RI = 0-13% -1991-95 (East): S or S/RI = 57-80% Quinine and Tetracycline -1994-95 (All areas):S/RI = 100 % Mefloquine monotherapy: -1991-97 (West): S or S/RI = 80%-97% -1992-97 (East): S or S/RI = 100%
Drug Resistance Monitoring in Cambodia 1998 • No study • Lack of budget • Lack of human resources due to Dengue epidemic outbreak
Chloroquine Mefloquine25mg Sampov Loun Chloroquine Rovieng Mefloquine25mg Mefloquine25mg/kgw Mefloquine25mg/kgw Drug Resistance of Chloroquine & Mefloquine Monotherapy 1999
Sampov Loun snoul Drug Resistance Artecomin Cambodia 1999 Artecom(Art.+piperaq.+trimethoprime) 2days,28days follow up
Sampov Loun Oral,Kg Speu Drug Resistance of A+M in Cambodia 2000
Samlot Snoul Drug Resistance of A+M Monitoring2001
3 Artekine2 42 Anlong Veng Artekine2 5 56 15 38 Coarterm Drug Resistance of Artekine 2 & Coarterm 2001
N=36 N=82 N=75 Drug Resistance Monitoring A+M in Cambodia 2002 Preah Vihear Ratanakiri Pailin Snoul Veal Veng
Sampov Loun Artekine 2 . Snoul N=55 N=65 Coarterm Drug Resistance of Artekine 2 & Coarterm in Cambodia 2002
Drug Resistance Monitoring A+M in Cambodia 2003 a = PCR confirmed all cases are recrudescing b = Showed that both are re – infection c = PCR confirmed all cases are recrudescing PCR were done by Institute Pasteur of Cambodia
Drug Resistance Monitoring at sentinel sites, Cambodia 2002 & 2003
Conclusion The result showed the sensitivity of A+M still high (ACPR = 92 – 100%) each sentinel site if we compared to the result of previous study. So The A+M can be continue as drug for our first line treatment of malaria.